Clinical Trial

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2024-10-09; most recent amendment 2026-07-08.
Status change: Recruiting → Active, Not Recruiting 2025-10-21
Status change: Not Yet Recruiting → Recruiting 2024-11-27
Trial Details
NCT Number NCT06637501
Lead Sponsor BeOne Medicines
Conditions Chronic Lymphocytic Leukemia
Enrollment 94 participants
Start Date 2024-11-14
Primary Completion 2026-11 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-09